Comparing Tetrahydrocannabinol (10 mg) with Tetrahydrocannabinol (25 mg) for cannabis intoxication

Exclusion

• −Allergy, sensitivity, intolerance, or dietary restriction preventing consumption study products
• −Self-reported confirmation of a HIV-, Hepatitis B- and/or C-positive diagnosis as assessed by the QI
• −Current and ongoing neurological or ophthalmological issue that could affect the retina (blindness, glaucoma, dry eyes, retinal diseases, pupil abnormalities, cataracts, sensitivity to bright lights)
• −Current or history of psychological disorders (e.g., schizophrenia and psychosis)
• −Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI
• −Type I or Type II diabetes with diabetic retinopathy
• −Unstable metabolic disease or chronic diseases as assessed by the QI
• −Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI (see below)
• −Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis
• −History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months
• −Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
• −Individuals with an unstable autoimmune disease
• −Alcohol or drug abuse within the last 12 months
• −Impairment from illicit drugs or alcohol during their study visit, as assessed by the QI or Sub-InvestigatorPrincipal investigatorThe doctor or researcher responsible for running the study at a site.Read more →
• −Alcohol intake average of \>2 standard drinks per day as assessed by the QI
• −Current use of prescribed and/or over-the-counter (OTC) medications, supplements, and/or consumption of food/drinks that may impact the efficacy and/or safety of the investigational product (see below)
• −Participation in other research studies 30 days prior to baselineBaselineYour starting measurements, taken before treatment begins.Read more →, as assessed by the QI
• −Individuals who are cognitively impaired and/or who are unable to give informed consentInformed consentThe process of being told what taking part involves, then choosing freely.Read more →
• −Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant
• −Individuals who are pregnant, breast feeding or planning to become pregnant during the study
• −History of surgery on eyes or retinas except for laser corneal surgery
• −Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI
• −Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow upFollow-upContinued check-ins after the treatment part is finished.Read more → that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable